The US Food & Drug Administration (FDA) has advised GTx to stop development of GTx-758 (also known as Capesaris), its oral drug intended for the treatment of men with advanced prostate cancer, after it became apparent that there was an increase in risk for blood clots in men taking active drug compared to those being treated with a placebo. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: blood clots, Capesaris, complications, GTx-758, risk | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 